CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine-Reference-Cited by-同舟云学术

CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine

Published:2007-07-05 Issue:9 Volume:21 Page:1937-1944
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Raj K,John A,Ho A,Chronis C,Khan S,Samuel J,Pomplun S,Thomas N S B,Mufti G J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404796.pdf

Reference34 articles.

1. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standa. Blood 2000; 96: 3671–3674.

2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

3. Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005; 19: 2223–2231.

4. Fukumoto JS, Greenberg PL . Management of patients with higher risk myelodysplastic syndromes. Crit Rev Oncol/Hematol Acute Leukemias 2005; 56: 179–192.

5. Teofili L, Morosetti R, Martini M, Urbano R, Putzulu R, Rutella S et al. Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation. Exp Hematol 2000; 28: 519–526.

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The roles of phosphorylation of signaling proteins in the prognosis of acute myeloid leukemia;Pathology and Oncology Research;2024-07-05

2. Pre-transplant therapy for patients with myelodysplastic syndromes: A systematic review and meta-analysis;Leukemia Research;2021-11

3. Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings;Acta Medica Bulgarica;2021-10-01

4. Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism;Frontiers in Oncology;2021-09-28

5. Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia;Pharmaceuticals;2021-07-04